ClinicalTrials.gg
Active, not recruitingNCT05059522Updated Oct 20, 2026

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

A Phase 3 interventional study of Avelumab and Lorlatanib in Advanced Malignancies, NSCLC and Ovarian Cancer, sponsored by Pfizer. Active, not recruiting at 71 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
77
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 38 studies in Ovarian Neoplasms by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Ovarian Neoplasms · Pfizer.

Enrollment
17th of 38
77 · median 52
Started
2021
with 5 others
Phase 3
5 of 38
none open now
Registered
27th of 38
by date

Among the 38 studies in Ovarian Neoplasms by Pfizer, this one is the 17th largest by enrollment, is one of 6 that started in 2021, is one of 5 in phase 3, and was the 27th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

1 of the 38 studies in Ovarian Neoplasms by Pfizer is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Ovarian Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Read the detailed description

B9991046 is a master protocol that will consist of sub-studies from the following parent studies:

B9991001 - NCT02603432 B9991003 - NCT02684006 B9991004 - NCT02554812 B9991005 - NCT02584634 B9991009 - NCT02580058 B9991023 - NCT03317496 B9991025 - NCT03330405 B9991027 - NCT03472560 B9991032 - NCT03565991

03

Conditions studied

  • Advanced Malignancies
  • NSCLC
  • Ovarian Cancer
  • Urothelial Cancer
  • Solid Tumors

Browse trials for

Keywords

  • BRCA Mutant Tumors
  • ATM Mutant Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Any participant who is receiving study treatment and deriving significant clinical benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored Avelumab Parent Study.
  2. Participants must agree to follow the reproductive criteria.
  3. Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Female participants who are pregnant or breastfeeding.
  2. Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Arm 1

    Avelumab monotherapy as specified by sub-study protocol B9991001C

    Drug: Avelumab

  • Experimental
    Arm 2

    Avelumab in combination with CMP 001, Utomilumab or PF04518600 as specified by sub-study protocol B9991004C

    Drug: Avelumab · Drug: CMP 001 · Drug: Utomilumab · Drug: PF04518600

  • Experimental
    Arm 3

    Avelumab in combination with Loratanib as specified by sub-study protocol B9991005C

    Drug: Avelumab · Drug: Lorlatanib

  • Experimental
    Arm 4

    Avelumab monotherapy as specified by sub-study protocol B9991009C

    Drug: Avelumab

  • Experimental
    Arm 5

    Avelumab monotherapy or in combination with Pemetrexed as specified by sub-study protocol B9991023C

    Drug: Avelumab · Drug: Pemetrexed

  • Experimental
    Arm 6

    Avelumab in combination with Talazoparib as specified by sub-study B9991025C.

    Drug: Avelumab · Drug: Talazoparib

  • Experimental
    Arm 7

    Avelumab in combination with Axitinib as specified by sub-study B9991027C.

    Drug: Avelumab · Drug: Axitinib

  • Experimental
    Arm 8

    Avelumab in combination with Talazoparib as specified by sub-study B9991032C.

    Drug: Avelumab · Drug: Talazoparib

  • Experimental
    Arm 9

    Avelumab in combination with Axitinib as specified by sub-study protocol B9991003C

    Drug: Avelumab · Drug: Axitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events leading to permanent discontinuation of study intervention

    Time frame: Baseline up to approximately 5 years

  2. Number serious adverse events reported for all participants

    Time frame: Baseline up to approximately 5 years

07

Study locations

71 sites
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 63 months is above that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2021
First posted
Sep 28, 2021
StartActual
Sep 29, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05059522
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 28, 2021
Start date
Sep 29, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 20, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avelumab

Start the discussion